SWOG clinical trial number
CTSU/EA5231
A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Open
Phase
Abbreviated Title
CLEAR
Status Notes
CTSU/EA5231 has been endorsed and activated by SWOG, effective 6/13/2025. CTSU/EA5231 was activated by ECOG-ACRIN, effective 6/13/2025.
Activated
06/13/2025
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE
Research committees
Lung Cancer
Treatment
durvalumab
Ceralasertib
Other Clinical Trials
SWOG Clinical Trial Number
S2409
PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231
A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase
SWOG Clinical Trial Number
S2414
INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Management and Survivorship
Activated
03/14/2025
Accrual
2%
Open
Phase